NEW YORK (GenomeWeb News) – Dutch firm InteRNA Technologies today said that it has joined the SIROCCO research consortium, a group of 25 labs and companies from 10 countries studying the use of RNA silencing for therapeutic applications, such as treating cancer.
SIROCCO stands for “Silencing RNAs: organizers and coordinators of complexity in eukaryotic organisms.”
InteRNA said that it will focus its efforts as part of the consortium on discovery, data mining, and development of diagnostic miRNA and other small RNA profiles through next-generation sequencing in combination with its own small RNA bioinformatics products.
The firm will participate in the remaining two and a half years of the project, which was funded with €11.8 million ($15 million) under the EU Sixth Framework Programme.